

Relationship Between Genotypes of Hepatitis C Virus and the Progression to Cirrhosis in Chronic Hepatitis C Patients

Colțescu Camelia¹, Doffoel M¹, Habersetzer F¹, Oltean G², Copotoiu Ruxandra³, Georgescu D⁴, Bătagă Simona⁴

¹ Department of Hepato-gastroenterology, Faculty of Medicine, University Louis Pasteur, Strasbourg, France

² Department of Internal Medicine, Medical Clinic 1, Faculty of Medicine, University of Medicine and Pharmacy, Tîrgu Mureș, Romania

³ Department of Anesthesiology, Faculty of Medicine, University of Medicine and Pharmacy, Tîrgu Mureș, Romania

⁴ Department of Gastroenterology, Medical Clinic 1, Faculty of Medicine, University of Medicine and Pharmacy, Tîrgu Mureș, Romania

Objective: To assess the influence of genotype on the stage of liver fibrosis in case of hepatitis C at the moment of identification and at the 5 years follow-up.

Methods: In our retrospective study we enrolled 126 patients with hepatitis C admitted to the Gastroenterology Unit of the Nouvel Hopital Civil in Strasbourg, France between October 2006 and December 2011. All patients had detectable serum HCV-RNA and had not been transplanted during the 5 years surveillance period. The collected data was analyzed with GraphPad Prism Demo for descriptive and inferential statistics and with StatMate2Demo for power analysis.

Results: Genotype distribution was as follows: genotype 1a, n=23 (18.25%); genotype 1b, n=48 (38.10%); genotype 2, n=17 (13.50%); genotype 3, n=18 (14.29%) and genotype 4, n=20 (15.86%). Fibrosis at diagnosis and follow-up was not influenced by the genotype (odds ratio ranging from 0.395 to 5.147 but with a 95% CI below 1), except genotype 1b (odds ratio 2.093 [1.008; 4.348] at follow-up).

Conclusions: There is no association between a particular HCV genotype and the stage of fibrosis as defined by transient elastography.

Keywords: fibrosis, genotype, HCV, cirrhosis, fibroscan

Received: 9 May 2012 / Accepted: 13 August 2012

Introduction

Hepatitis C virus (HCV) is estimated to affect approximately 200 million people worldwide with a global prevalence of 3% [1]. More than 80% of patients with HCV infection progress to chronicity, 20–30% of patients with chronic HCV infection progress to cirrhosis in 10 to 20 years, which in turn is associated with an increased risk of hepatocellular carcinoma [2].

Virological studies have identified six genotypes (1–6) of HCV and various subtypes [3].

The most prevalent genotype worldwide is genotype 1 (1a and 1b), subtype 1b having the highest prevalence in Europe. Genotypes 5 and 6 are less frequent.

HCV RNA testing, HCV genotyping and staging of liver disease are essential for the diagnosis and HCV-treatment. Liver biopsy is the gold standard in assessing liver fibrosis in patients with chronic HCV infection. Several types of fibrosis classifications are now available for non-invasive fibrosis tests (Fibrotest, Fibroscan, FibroMeter), the most important of which is detailed fibrosis class classifications [4,5]. Recently, non-invasive methods (transient elastography, serological markers) have been used for identifying patients with mild fibrosis and cirrhosis, but their accuracy is less reliable in discriminating moderate and severe fibrosis. The European Association of the Study of the Liver hepatitis C virus clinical practice guidelines of 2011 recommend that transient elastography be used

to assess liver fibrosis in patients with chronic hepatitis C [6]. Transient elastography is a simple, non-invasive and effective method to assess liver fibrosis by measuring liver stiffness [7].

Material and method

Our retrospective study enrolled 126 patients with hepatitis C admitted to the Gastroenterology Unit of the Nouvel Hopital Civil in Strasbourg, France between October 2006 and December 2011. The inclusion criteria were: detectable serum HCV-RNA, patients aged above 18 years, clearly identified genotype, a 5-year follow-up, fibrosis evaluation by transient elastography at identification and follow-up, viral load, general biochemistry done on a regular basis. The exclusion criteria were: liver transplantation during the surveillance period and missing follow-up sessions.

All laboratory tests were performed for each patient on enrollment. They were measured using commercially available assays. HCV genotype was determined by Bayer Trugene HCV 5'NC sequence and NS5B Applied Biosystems 3130 and classified according to Simmonds' classification system. Serum viral load was determined by quantitative reverse transcription polymerase chain reaction with Abbot real-time PCR from 2008 on and by signal amplification on the branched DNA probe (Bayer bDNA Quantiplex 3.0) until 2008.

For the identification and evaluation of fibrosis we used the transient elastography method (FibroScan® Echosens, Paris, France). We graded the fibrosis, according to META-




Fig. 1. Distribution of severe and minimal to moderate fibrosis on identification

VIR staging, into minimal to moderate (F0 to F2 staging) and severe (F3 and F4 staging).

The collected data was analyzed with GraphPad Prism Demo for descriptive and inferential statistics – odds ratio, proportions comparison, Fischer test for ordinal variables, and with StatMate2Demo for power analysis. P values below 0.05 were considered to be statistically significant.

Results

Given the number of patients included, and considering a significant variation of 0.2, our study had a power of 60%. A power of 80%, for identifying a 0.1 change would require the enrollment of 500 patients. That does not mean that our study is not clinically important.

The demographic data were as follows: 67 males (53.17%) and 59 females (46.83%) with an average age of 50.15 ± 10.55 years. Genotype distribution was as follows: genotype 1a, $n=23$ (18.25%); genotype 1b, $n=48$ (38.10%); genotype 2, $n=17$ (13.50%); genotype 3, $n=18$ (14.29%) and genotype 4, $n=20$ (15.86%).

Severe fibrosis was identified at diagnosis in 39 patients (30.95%) and in 53 patients (42.06%) at follow-up ($p=0.0887$). The distribution of severe and minimal to moderate fibrosis as seen by FibroScan on diagnosis and follow-up is depicted in Figures 1 and 2.

The odds ratios associated with each genotype are presented in Table I.

Table I. Odds ratio for genotype on admission and at follow-up

Genotype	On admission (odds ratio 95% CI)	At follow-up (odds ratio 95% CI)
1a	2.714 [1.059; 6.960]	1.844 [0.729; 4.659]
1b	1.805 [0.837; 3.891]	2.093 [1.008; 4.348]
2	0.259 [0.056; 1.196]	0.529 [0.174; 1.607]
3	0.400 [0.107; 1.472]	0.480 [0.160; 1.443]
4	0.507 [0.157; 1.631]	0.408 [0.136; 1.189]




Fig. 2. Distribution of severe and minimal to moderate fibrosis at follow-up

Despite the suggestive graphic representation, there is no statistical significance associated with the genotype and the fibrosis staging, except for genotype 1b.

Discussion

The HCV genotype must be assessed prior to antiviral treatment initiation [6].

Recently, many factors have been reported to predict the outcome of treatment, such as HCV genotype, treatment duration, age and patients' gender. The serum viral load has been revealed as one of the critical predictors, despite of HCV genotype [8]. Other studies reported that the viral loads did not correlate with the stage of liver disease, but these studies were conducted on small cohorts of patients or on patients infected mainly with genotype 1b [9]. Fibrosis stages were independent of the genotype of patients; serum viral load, aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin levels were significantly different among fibrosis stages [10]. But it is true that the fibrosis/cirrhosis were assessed by liver biopsy.

While a higher necro-inflammatory activity could be associated with HCV genotype 2 and with higher ALT serum levels, no association could be proved between HCV genotype and progression of liver disease.

A study enrolling 324 patients indicates that there is no association between a particular HCV genotype and the progression to cirrhosis, and that specific genotypes are associated with distinct histopathological and biochemical manifestations, although none of them is correlated with an increase of the fibrosis stage [11]. The authors of this study also used liver biopsy to fundament their research. Using transient elastography, genotype 1b seems to be more aggressive – there is a significantly higher incidence of fibrosis at follow-up.

Our findings are yet to be confirmed by prospective multicentric studies with multivariate analysis focusing on

treatment. We have to emphasize that patients receiving a liver transplant in the 5-year period of follow-up were excluded. Maybe the results would be different if this period of follow-up would be shortened. If our results are proven to be true, a change in treatment approach should be sought after.

The results of a recent prospective study conducted in a large cohort of patients with chronic liver disease showed that transient elastography is an efficient technique for the diagnosis of cirrhosis and its severity [12]. Apparently this technique replaces liver biopsy. Further analysis of these differences will provide us with more effective treatment strategies according to HCV genotype. Maybe it is time to change the golden standard.

Transient elastography is a relative newly acquired tool, so the number of studies is rather limited.

Conclusions

Our study shows that there is no association between a particular HCV genotype and the fibrosis stage as defined by transient elastography. Further multicentric studies are needed in order to increase the power of the study, to refine the statistics and to validate our findings.

References

1. World Health Organization (WHO). Hepatitis C – global prevalence (update). *Wkly Epidemiol Rec.* 2000;75:18-19.
2. Hwang SJ. Hepatitis C virus infection: an overview. *J Clin Microbiol Immunol Infect.* 2001;34:227-234.
3. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology.* 2005;42:962-273.
4. Boursier J, Bertrais S, Oberti F, et al. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. *BMC Gastroenterology.* 2011;11:132.
5. de Ledinghen V, Vergniol J. Transient elastography (Fibroscan). *Gastroenterol Clin Biol.* 2008;32:58-67.
6. Calvaruso V, Craxi A. 2011 European Association of the study of de Liver hepatitis C virus clinical practice guidelines. *Liv Int.* 2012;32(S1):2-8.
7. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology.* 2005;128:343-350.
8. Iwasaki Y, Shiratori Y, Hige S, et al. A randomized trial of 24 versus 48 weeks of peginterferon alpha- 2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. *Hepatol Int.* 2009;3:468-479.
9. Sato S, Genda T, Hirano K, et al. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C. *Hepatol Int.* 2011 Apr 2 [Epub ahead of print].
10. Ijaz B, Ahmad W, Javed F, et al. Association of laboratory parameters with viral factors in patients with hepatitis C. *Virology Journal.* 2011;8:361.
11. Adinolfi LE, Utili R, Andreana A, et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. *Eur J Gastroenterol Hepatol.* 2000;12:299-304.
12. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (fibroscan): a prospective study. *Gut.* 2006;55:403-408.